Strict Action Warning Issued Over New Price Caps on Cancer Drugs

The National Pharmaceutical Pricing Authority has warned of penal action against anyone who fails to follow the revised prices for 137 anti-cancer drugs. The authority functions under the Department of Pharmaceuticals. State drug controllers must strictly monitor these prices and send in their action taken reports by November 16, according to an official release on Friday, November 13, 2026.

Implementation

The revised prices for these 137 medicines took effect on November 9, 2026. This follows a gazette order issued on October 17, 2026. The order capped the trade margin on these drugs at 30 percent. Based on details shared by drug companies up to November 11, the updated price lists are now available on the pricing authority website and the Pharma Sahi Daam app and portal, as stated by the Chemicals and Fertilizers Ministry.

Compliance

All makers, stockists, dealers, shop owners, hospitals, and medical centres must follow the revised prices. They must also prominently display the updated price lists at their offices and on their websites. State drug controllers must check compliance across the entire supply chain and healthcare centres so patients actually get the benefit of the lower maximum retail prices. Any violation can lead to overcharging proceedings under the provisions of the Drug Prices Control Order of 2013. People can report overcharging, shortages, or medicine unavailability through the Pharma Sahi Daam app or portal, the pricing authority helpline at 1800-111-255, or via email at monitoring-nppa@gov.in.

Context

The National Pharmaceutical Pricing Authority works to make essential medicines more affordable for the public by keeping strict checks on market pricing. Capping trade margins on critical treatments like cancer drugs helps reduce the heavy financial burden on patients and their families. State drug controllers play a key role in enforcing these orders locally across hospitals and retail shops.